CGEN News and Press, Compugen Ltd. From 11/07/25

2025-11-07 10:37:59 ET More on Compugen Compugen Stock: Runway Into 2027 But Expensive Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen Read the full article on Seeking Alpha ...

2025-11-04 09:34:07 ET https://markets-headlines.com/wp-content/uploads/2025/11/FDA-Opens-the-Door-for-AI-in-Clinics-Priming-Market-for-2.7T-Digital-Health-Wave-by-2035-1.mp4 Issued on behalf of Aleen Inc. ...

Compugen to Participate in Stifel 2025 Healthcare Conference PR Newswire HOLON, Israel , Nov. 4, 2025 /PRNewswire/ --  Compugen Ltd.  (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target dis...

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 PR Newswire HOLON, Israel , Oct. 27, 2025 /PRNewswire/ --  Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug...

2025-10-27 04:01:20 ET ... Read the full article on Seeking Alpha For further details see: Compugen Stock: Runway Into 2027 But Expensive

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 PR Newswire Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier settin...

Compugen to Present at SITC 2025 PR Newswire HOLON, Israel , Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML toda...

Compugen to Present Research at the Single Cell Genomics 2025 Conference PR Newswire HOLON, ISRAEL , Sept. 8, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computationa...

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference PR Newswire HOLON, Israel , Aug. 28, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive ...

2025-08-08 05:13:50 ET Compugen ( CGEN ) is gearing up for several catalysts over the next few years. Its key program is the development of its potential best-in-class anti-PVRIG antibody COM701 which is being explored in the ongoing phase 1/2 MAIA-ovarian study targ...